Healthcare / BiotechnologyNasdaqGS
$1.21
-0.04 (-3.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-168.6M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$776M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-37.0%
↓Gross Margin
97.4%
↑Debt/Equity
0.54
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2009–2025 · 16 años de histórico normalizado
Revenue CAGR
+33.9%
FCF CAGR
—
FCF margin
-60.4%
FCF / Net income
1.33x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $183.9M · net income $-83.5M · FCF $-111.1M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||||||
| Revenue | $183.9M | $183.9M | $77.0M | $237000.00 | $596000.00 | $1.4M | $253000.00 | $460000.00 | $1.1M | $1.1M | $6.2M | $36.4M | $1.2M | $1.3M | $2.7M | $2.4M | $3.6M | $1.7M |
| Net Income | $-83.5M | $-83.5M | $-174.6M | $-184.1M | $-141.9M | $-116.1M | $-75.6M | $-68.5M | $-27.0M | $-27.9M | $-29.5M | $46000.00 | $-35.7M | $-38.4M | $-68.9M | $-96.9M | $-111.4M | $-70.2M |
| EBITDA | $-49.6M | $-49.6M | $-154.8M | $-174.8M | $-134.2M | $-113.8M | $-76.8M | $-72.4M | — | — | — | — | — | — | — | — | — | — |
| EPS | -0.13 | -0.13 | -0.27 | -0.32 | -0.37 | -0.35 | -0.28 | — | — | -0.18 | -0.19 | 0.00 | -0.23 | -0.30 | — | — | — | — |
| Gross Margin | 97.4% | 97.4% | 98.4% | 100.0% | 100.0% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | -28.0% | -28.0% | -225.6% | -81832.9% | -23246.6% | -8183.7% | -30400.4% | -15762.0% | -2914.9% | -2746.9% | -497.3% | -1.5% | -3149.3% | -3036.5% | -2648.9% | -3942.4% | -3120.0% | -4069.2% |
| Net Margin | -45.4% | -45.4% | -226.7% | -77690.7% | -23808.9% | -8335.4% | -29888.1% | -14901.7% | -2534.4% | -2621.2% | -479.3% | 0.1% | -3093.7% | -2991.3% | -2542.7% | -3972.6% | -3125.9% | -4066.3% |
| Balance Sheet | ||||||||||||||||||
| Debt/Equity | 0.54 | 0.54 | 0.43 | 0.35 | 0.70 | 0.39 | 0.11 | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 6.78 | 6.78 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||||||||||
| Free Cash Flow | $-111.1M | $-111.1M | $-219.3M | $-168.6M | $-127.8M | $-95.8M | $-67.1M | $-44.2M | $-21.0M | — | $-18.4M | $-24.3M | — | — | — | $-63.0M | $-45.1M | $-44.8M |
| Returns | ||||||||||||||||||
| ROE | -37.0% | -37.0% | -62.3% | -74.3% | -177.4% | -91.8% | -35.8% | -50.7% | -15.2% | -26.9% | -24.1% | 0.0% | -27.3% | -64.2% | -80.4% | -66.1% | -57.8% | -40.7% |
| Valuation | ||||||||||||||||||
| P/B | 3.57 | 3.57 | 8.23 | 4.63 | 11.90 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | ||||||||||||||||||
| Revenue Growth | 138.8% | 138.8% | 32386.9% | -60.2% | — | 450.6% | -45.0% | -56.8% | 0.1% | -82.7% | -83.1% | 3054.5% | -10.1% | -52.6% | 11.1% | -31.6% | 106.4% | — |
| EPS Growth | 51.9% | 51.9% | 15.6% | 13.5% | — | -25.0% | — | — | — | 5.3% | — | 100.0% | 23.3% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.4%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.27 → -0.13
Residual
-20.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.